Qin Ziyao, Zheng Mei
No. 4 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai 200051, P.R. China.
Exp Ther Med. 2023 Jul 13;26(3):416. doi: 10.3892/etm.2023.12115. eCollection 2023 Sep.
Melanoma is the most aggressive and deadly type of skin cancer and is known for its poor prognosis as soon as metastasis occurs. Since 2011, new and effective therapies for metastatic melanoma have emerged, with US Food and Drug Administration approval of multiple targeted agents, such as V-Raf murine sarcoma viral oncogene homolog B1/mitogen-activated protein kinase kinase inhibitors and multiple immunotherapy agents, such as cytotoxic T lymphocyte-associated protein 4 and anti-programmed cell death protein 1/ligand 1 blockade. Based on insight into the respective advantages of the above two strategies, the present article provided a review of clinical trials of the application of targeted therapy and immunotherapy, as well as novel approaches of their combinations for the treatment of metastatic melanoma in recent years, with a focus on upcoming initiatives to improve the efficacy of these treatment approaches for metastatic melanoma.
黑色素瘤是最具侵袭性和致命性的皮肤癌类型，一旦发生转移，其预后就很差。自2011年以来，出现了针对转移性黑色素瘤的新型有效疗法，美国食品药品监督管理局批准了多种靶向药物，如V- Raf鼠肉瘤病毒癌基因同源物B1/丝裂原活化蛋白激酶激酶抑制剂，以及多种免疫治疗药物，如细胞毒性T淋巴细胞相关蛋白4和抗程序性细胞死亡蛋白1/配体1阻断剂。基于对上述两种策略各自优势的深入了解，本文综述了近年来靶向治疗和免疫治疗应用于转移性黑色素瘤的临床试验，以及它们联合应用的新方法，重点关注提高这些治疗方法对转移性黑色素瘤疗效的未来举措。
